Control of AMP deaminase 1 binding to myosin heavy chain
1 Departments of Medicine, Genetics, and Biochemistry, University of Pennsylvania School of Medicine, Philadelphia 19104-4283; 2 Howard Hughes Medical Institute and Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6148; and...
Gespeichert in:
Veröffentlicht in: | American Journal of Physiology: Cell Physiology 1998-09, Vol.275 (3), p.C870-C881 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | 1 Departments of Medicine,
Genetics, and Biochemistry, University of Pennsylvania School of
Medicine, Philadelphia 19104-4283;
2 Howard Hughes Medical Institute
and Department of Biochemistry and Biophysics, University of
Pennsylvania School of Medicine, Philadelphia, Pennsylvania
19104-6148; and 3 The 1st
Department of Medicine, Tottori University Faculty of Medicine,
Yonago 683, Japan
AMP deaminase (AMPD) plays a central role in preserving the
adenylate energy charge in myocytes following exercise and in producing
intermediates for the citric acid cycle in muscle. Prior studies have
demonstrated that AMPD1 binds to myosin heavy chain (MHC)
in vitro; binding to the myofibril varies with the state of muscle
contraction in vivo, and binding of AMPD1 to MHC is required for
activation of this enzyme in myocytes. The present study has identified
three domains in AMPD1 that influence binding of this enzyme to MHC
using a cotransfection model that permits assessment of mutations
introduced into the AMPD1 peptide. One domain that encompasses residues
178-333 of this 727-amino acid peptide is essential for binding of
AMPD1 to MHC. This region of AMPD1 shares sequence similarity with
several regions of titin, another MHC binding protein. Two additional
domains regulate binding of this peptide to MHC in response to
intracellular and extracellular signals. A nucleotide binding site,
which is located at residues 660-674, controls binding of AMPD1 to
MHC in response to changes in intracellular ATP concentration. Deletion
analyses demonstrate that the amino-terminal 65 residues of AMPD1 play
a critical role in modulating the sensitivity to ATP-induced inhibition
of MHC binding. Alternative splicing of the AMPD1 gene product, which alters the sequence of residues 8-12, produces two AMPD1 isoforms that exhibit different MHC binding properties in the presence of ATP.
These findings are discussed in the context of the various roles
proposed for AMPD in energy production in the myocyte.
purine nucleotide cycle; adenylate energy charge; skeletal muscle
bioenergetics |
---|---|
ISSN: | 0363-6143 0002-9513 1522-1563 |
DOI: | 10.1152/ajpcell.1998.275.3.c870 |